THE BLADDER CANCER COMPANY

Photocure ASA: Notification of primary insider transactions

Oslo, Norway, August 7, 2026 – Chairman of the Board of Directors Dylan Hallerberg has acquired 20,658 shares at an average price of NOK 48.48. Board member Neal Shore has acquired 27,675 shares at an average price of NOK 48.70.

Primary insider notification pursuant to the market abuse regulation article 19 is attached.

For further information, please contact:

Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com

About Photocure ASA

Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news